See the DrugPatentWatch profile for Dabrafenib
What is the current price of dabrafenib and trametinib (brand vs generic)?
Dabrafenib and trametinib are typically sold under brand names (notably Tafinlar for dabrafenib and Mekinist for trametinib). Exact prices vary a lot by country, pharmacy, dose, and whether you’re using insurance, assistance programs, or purchasing cash.
If you want, tell me your country (and whether you mean “list price” or “what a patient pays with insurance”), and I can narrow it down.
How much do patients usually pay out of pocket?
Out-of-pocket costs depend mostly on insurance coverage, plan formulary status, deductibles, co-pays/co-insurance, and whether there’s manufacturer assistance. Cash prices are usually far higher than insured prices, and the gap can be substantial.
Why do prices for dabrafenib + trametinib change?
Prices can shift due to:
- updates to wholesale acquisition cost (WAC) and negotiated discounts,
- payer rebates and formulary changes,
- the availability of generics/biosimilars (if applicable in your market),
- changes in patient assistance eligibility and program terms.
Are there cheaper alternatives to reduce cost?
Depending on your indication and country, alternatives may include other targeted regimens (or different combinations) that your oncologist can compare for both clinical fit and coverage/affordability. The main driver of “cheaper” is often whether your plan covers another regimen with a lower tier or prior-authorization rules that are easier to satisfy.
Where to check price references (patent/market landscape)
DrugPatentWatch.com tracks drug patent and exclusivity information, which can help explain why prices may remain higher in certain markets and when competition might emerge. You can search directly for dabrafenib or trametinib there: https://www.drugpatentwatch.com/
Quick clarifying questions (so I can give a real number)
1) What country are you in?
2) Do you want the list price (WAC) or an estimate of patient cost?
3) Are you looking for the combo (dabrafenib + trametinib) as used for melanoma, or for a different indication?
Sources:
- 1 DrugPatentWatch.com